Lung cancer staging
LT Tanoue - Clinics in chest medicine, 2020 - chestmed.theclinics.com
Staging is a critical step in the evaluation of every patient with lung cancer. Although
breakthroughs in understanding of lung cancer molecular and immunologic variability have …
breakthroughs in understanding of lung cancer molecular and immunologic variability have …
[HTML][HTML] Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
M Łazar-Poniatowska, A Bandura… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally
advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) …
advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) …
[HTML][HTML] Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck
X Mielgo-Rubio, F Rojo, L Mezquita-Pérez… - World Journal of …, 2020 - ncbi.nlm.nih.gov
After publication of the PACIFIC trial results, immune checkpoint inhibitor-based
immunotherapy was included in the treatment algorithm of locally advanced non-small cell …
immunotherapy was included in the treatment algorithm of locally advanced non-small cell …
[HTML][HTML] Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer
M Gouran-Savadkoohi, A Mesci, GR Pond… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Radiotherapy (RT) is used as monotherapy in poor performance patients with
unresected locally advanced non-small cell lung cancer (LA-NSCLC), but their outcomes …
unresected locally advanced non-small cell lung cancer (LA-NSCLC), but their outcomes …
Not following the rules in guideline care for lung cancer diagnosis and staging has negative impact
CL Wilshire, JR Rayburn, SC Chang, CR Gilbert… - The Annals of thoracic …, 2020 - Elsevier
Background Recent studies have identified poor adherence to recommended guidelines in
diagnosing and staging patients with non-small cell lung cancer (NSCLC), and this practice …
diagnosing and staging patients with non-small cell lung cancer (NSCLC), and this practice …
[HTML][HTML] The impact of staging FDG-PET/CT on treatment for stage III NSCLC-an analysis of population-based data from Ontario, Canada
CA Beers, GR Pond, JR Wright, T Tsakiridis… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Purpose Fluoro-2-deoxyglucose positron-emission tomography (FDG-PET/CT) is now
considered a standard investigation for the staging of new cases of stage III NSCLC …
considered a standard investigation for the staging of new cases of stage III NSCLC …
[HTML][HTML] Resveratrol sensitizes A549 cells to irradiation damage via suppression of store‑operated calcium entry with Orai1 and STIM1 downregulation
W Lele, L Lei, Q Liting - Experimental and Therapeutic …, 2021 - spandidos-publications.com
Resveratrol is a natural polyphenol with multiple positive biofunctions and was found to
have potential as a radiosensitizer with an intricate molecular mechanism. Store‑operated …
have potential as a radiosensitizer with an intricate molecular mechanism. Store‑operated …
[HTML][HTML] Development and validation of a prognostic nomogram model in locally advanced NSCLC based on metabolic features of PET/CT and hematological …
C Wang, J Fang, T Jiang, S Hu, P Wang, X Liu, S Zou… - EJNMMI physics, 2024 - Springer
Background We combined the metabolic features of 18F-FDG-PET/CT and hematological
inflammatory indicators to establish a predictive model of the outcomes of patients with …
inflammatory indicators to establish a predictive model of the outcomes of patients with …
Setting the stage for success in lung cancer: the importance of remembering your (guide) lines
BC Bade, GA Silvestri - Chest, 2019 - journal.chestnet.org
Lung cancer staging is the basis for prognosis and treatment, and each lung cancer stage
has an expected survival and treatment paradigm. In general, patients with stage I disease …
has an expected survival and treatment paradigm. In general, patients with stage I disease …
Tumor and treatment parameters influencing radiotherapy outcomes in locally advanced (LA) non-small cell lung cancer (NSCLC)
M Gouran-Savadkoohi - 2022 - macsphere.mcmaster.ca
Introduction: Lung cancer is the leading cause of cancer death worldwide. In Canada, in
2021 alone, an estimated 21,000 patients have died from this disease. Non-small cell lung …
2021 alone, an estimated 21,000 patients have died from this disease. Non-small cell lung …